Moderna cut its 2025 sales forecast by $1 billion on Monday, hurt by a slow adoption of its respiratory syncytial virus (RSV) ...

Moderna has been awarded approximately $590 million from the federal government to help speed up the development of an ...

The US Department of Health and Human Services will award $590 million to Moderna to continue developing a vaccine to protect ...

J.P. Morgan analyst Jessica Fye has maintained their bearish stance on MRNA stock, giving a Sell rating yesterday.Stay Ahead of the ...

The public health risk remains low, but bird flu variants have proven to be unpredictable, which is why the virus is a top ...

Shares of Moderna dropped more than 20% intraday to $33.44, more than erasing gains last week after the first bird-flu death ...

Analyst Mani Foroohar of Leerink Partners maintained a Sell rating on Moderna (MRNA – Research Report), reducing the price target to ...

With a mission to expand mRNA's therapeutic possibilities, Kerna Labs is pushing the boundaries of what's possible in genetic medicine. "We're on the cusp of a major leap forward in genetic medicine, ...

Achieved 2024 product sales of $3.0 to 3.1 billion (unaudited) and an ending cash balance of approximately $9.5 billion (unaudited) ...

Moderna shares soared Tuesday as investors placed bets that the pharmaceutical giant’s development of an H5N1 bird flu vaccine could boost sales after the first death linked to the disease was ...